A noteworthy article from the CIA’s Studies in Intelligence Journal, published in 1979 and declassified last year, describes the use of “remote medical diagnosis” for foreign intelligence purposes.
“Remote medical diagnosis is defined as the identification of the illnesses affecting a person without the benefit of a formal medical examination.”
The authors provide capsule accounts of CIA medical diagnoses of various world leaders, including French President Georges Pompidou, Algerian President Houari Boumediene, Soviet Premier Leonid Brezhnev, and Israeli Prime Minister Menahem Begin.
The technique, such as it is, is far from infallible, the authors note. Although Israeli Prime Minister Golda Meir suffered from malignant lymphoma for more than 12 years, “We had been entirely unaware that she had this lethal disease.”
See “Remote Medical Diagnosis: Monitoring the health of Very Important Patients,” Studies in Intelligence, Spring 1979 (1.2 MB PDF file) (thanks to AT).
By preparing credible, bipartisan options now, before the bill becomes law, we can give the Administration a plan that is ready to implement rather than another study that gathers dust.
Even as companies and countries race to adopt AI, the U.S. lacks the capacity to fully characterize the behavior and risks of AI systems and ensure leadership across the AI stack. This gap has direct consequences for Commerce’s core missions.
The last remaining agreement limiting U.S. and Russian nuclear weapons has now expired. For the first time since 1972, there is no treaty-bound cap on strategic nuclear weapons.
As states take up AI regulation, they must prioritize transparency and build technical capacity to ensure effective governance and build public trust.